UCERIS TABLETS: A FOCUS ON STEROID-RELATED SAFETY
Profile of UCERIS tablets through 8 weeks1
Overall glucocorticoid-related side effects for UCERIS tablets and placebo at 8 weeks were 10.2% and 10.5%, respectively, in clinical trials.1†

†In a pooled analysis of 2 Phase III clinical trials.
SELECTED IMPORTANT SAFETY INFORMATION
- When glucocorticosteroids are used chronically, systemic effects such as hypercorticism and adrenal suppression may occur. Since UCERIS tablets are a glucocorticosteroid, general warnings concerning glucocorticoids should be followed
Study design: Two randomized, double-blind, placebo-controlled studies were conducted in a total of 970 adult patients with active, mild to moderate UC (UCDAI: ≥4 and ≤10 at entry). The primary endpoint was induction of combined clinical and endoscopic remission (defined as an Ulcerative Colitis Disease Activity Index [UCDAI] score of ≤1, with subscores of 0 for both rectal bleeding and stool frequency, normal mucosa with no friability on endoscopy, and a ≥1-point reduction in the Endoscopic Index [EI] score) after 8 weeks of treatment.1,2